Revenue Growth
Nuwellis generated $1.9 million in revenue for Q1 2025, representing a 3% increase year-over-year, supported by a 4% increase in consumables utilization and an increase in U.S. console sales.
Strong Growth in Pediatrics and Heart Failure
Pediatrics and heart failure segments saw 38% and 28% growth over the prior year, respectively, driven by an increase in consumable utilization.
Reduction in Operating Expenses
Operating expenses reduced by 31% compared to Q1 2024, with selling, general and administrative expenses down by 22% and research and development expenses down by 57.7%.
Improved Reimbursement Coverage
Effective January 1, Aquadex was reassigned to a new outpatient reimbursed level by CMS, increasing the facility reimbursement fee by nearly 4x to $1,639 per day.
Reduction in Net Loss
Net loss attributable to common shareholders was reduced to $3 million or a loss of $0.69 per share compared to a net loss of $3.8 million or $24.11 per share in Q1 2024.